Federated Hermes, Inc. Vanda Pharmaceuticals Inc. Transaction History

Federated Hermes, Inc.

$42.5 Billion
Q1 2024

A detailed history of Federated Hermes, Inc. transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 715,670 shares of VNDA stock, worth $3.66 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

715,670

Previous 818,027 12.51%

Holding current value

$3.66 Million

Previous $3.45 Million 14.8%

% of portfolio

0.01%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$3.47 - $4.61 $355,178 - $471,865	-102,357 Reduced 12.51%	715,670 $2.94 Million
Q4 2023 Jan 31, 2024	SELL	$3.38 - $4.58 $282,169 - $382,347	-83,482 Reduced 9.26%	818,027 $3.45 Million
Q3 2023 Nov 13, 2023	SELL	$4.28 - $6.57 $568,465 - $872,620	-132,819 Reduced 12.84%	901,509 $3.89 Million
Q2 2023 Aug 14, 2023	SELL	$5.9 - $6.95 $61,649 - $72,620	-10,449 Reduced 1.0%	1,034,328 $6.82 Million
Q1 2023 May 08, 2023	BUY	$6.18 - $7.99 $1.49 Million - $1.92 Million	240,859 Added 29.96%	1,044,777 $7.09 Million

Q4 2022 Feb 13, 2023	BUY	$6.87 - $10.96 $2.13 Million - $3.4 Million	310,073 Added 62.79%	803,918 $5.94 Million
Q3 2022 Nov 14, 2022	BUY	$9.44 - $11.76 $80,844 - $100,712	8,564 Added 1.76%	493,845 $4.88 Million
Q2 2022 Aug 15, 2022	SELL	$9.31 - $11.84 $495,859 - $630,610	-53,261 Reduced 9.89%	485,281 $5.29 Million
Q1 2022 May 13, 2022	SELL	$10.84 - $16.55 $44,682 - $68,219	-4,122 Reduced 0.76%	538,542 $6.09 Million
Q4 2021 Feb 14, 2022	SELL	$15.69 - $21.14 $82,027 - $110,519	-5,228 Reduced 0.95%	542,664 $8.51 Million
Q3 2021 Nov 15, 2021	BUY	$15.35 - $21.27 $540,703 - $749,235	35,225 Added 6.87%	547,892 $9.39 Million
Q2 2021 Aug 16, 2021	BUY	$15.71 - $21.51 $110,535 - $151,344	7,036 Added 1.39%	512,667 $11 Million
Q1 2021 May 13, 2021	BUY	$13.42 - $20.28 $551,642 - $833,629	41,106 Added 8.85%	505,631 $7.6 Million
Q4 2020 Feb 12, 2021	BUY	$9.77 - $13.81 $24,571 - $34,732	2,515 Added 0.54%	464,525 $6.1 Million
Q3 2020 Nov 12, 2020	BUY	$9.32 - $12.02 $1.9 Million - $2.45 Million	203,873 Added 78.98%	462,010 $4.46 Million
Q2 2020 Aug 13, 2020	BUY	$9.66 - $12.02 $145,547 - $181,105	15,067 Added 6.2%	258,137 $2.95 Million
Q1 2020 May 13, 2020	BUY	$7.5 - $16.8 $1.04 Million - $2.33 Million	138,973 Added 133.5%	243,070 $2.52 Million
Q4 2019 Feb 14, 2020	SELL	$12.38 - $17.47 $4.49 Million - $6.34 Million	-362,810 Reduced 77.7%	104,097 $1.71 Million
Q3 2019 Nov 14, 2019	BUY	$12.27 - $15.79 $2.87 Million - $3.69 Million	233,680 Added 100.19%	466,907 $6.2 Million
Q2 2019 Aug 14, 2019	SELL	$13.37 - $18.85 $292,361 - $412,192	-21,867 Reduced 8.57%	233,227 $3.29 Million
Q1 2019 May 10, 2019	BUY	$17.59 - $31.05 $2.13 Million - $3.76 Million	121,038 Added 90.29%	255,094 $4.69 Million
Q4 2018 Feb 13, 2019	BUY	$18.97 - $31.47 $2.53 Million - $4.19 Million	133,264 Added 16826.26%	134,056 $3.5 Million
Q3 2018 Nov 13, 2018	SELL	$18.25 - $23.0 $444,186 - $559,797	-24,339 Reduced 96.85%	792 $19,000
Q3 2017 Nov 13, 2017	BUY	$15.4 - $18.85 $387,017 - $473,719	25,131	25,131 $450,000

Others Institutions Holding VNDA

# of Institutions

147

Shares Held

49.6M

Call Options Held

49.1K

Put Options Held

107K

View Full List

About Vanda Pharmaceuticals Inc.

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $289M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

More about VNDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Vanda Pharmaceuticals Inc. Transaction History